TY - JOUR. T1 - Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. AU - Bartlett, David L.. AU - Libutti, Steven K.. AU - Figg, William D.. AU - Fraker, Douglas L.. AU - Richard Alexander, H.. PY - 2001/1/1. Y1 - 2001/1/1. N2 - Background. Unresectable colorectal liver metastases are a significant clinical problem. Isolated hepatic perfusion (IHP) is a regional treatment technique that delivers high dose chemotherapy, biologic agents, and hyperthermia via a completely isolated vascular recirculating perfusion circuit as a means of regionally treating liver tumors. This study presents our results of IHP with tumor necrosis factor (TNF) plus melphalan or IHP with melphalan alone followed by infusional floxuridine (FUDR) and leucovorin in patients with advanced or refractory unresectable hepatic colorectal metastases. Methods. Fifty-one patients with unresectable colorectal hepatic metastases underwent a 60-minute IHP with 1.5 mg/kg melphalan and hyperthermia ...
Addition of selective internal radiation therapy (SIRT) failed to improve progression-free survival in non-resectable colorectal cancer liver metastases.
Eicosapentaenoic acid (EPA) is a naturally occuring omega-3 polyunsaturated fatty acid found in oily fish. EPA has anti-colorectal (bowel) cancer activity in experimental models. This trial will test whether EPA reduces markers of tumour growth, and is safe and well tolerated,in patients with colorectal cancer liver metastases awaiting surgery ...
Estrogen plays an important role in the development of some cancers. However, previous studies on the influence of estrogen on colorectal cancer (CRC) have had conflicting conclusions, and there have been few reports on estrogens and liver metastasis. The aim of this study was to explore the prognostic impact of estrogens on CRC with liver metastasis. Eighty-six patients with CRC including 43 synchronous liver metastases were studied. Estrogen receptor β (ERβ) levels were assayed by immunohistochemistry in liver metastasis, CRC and adjacent normal tissues. Serum estrogen levels were measured by radioimmunoassay. The correlation between staining, clinicopathological parameters, and prognostic power were analyzed statistically. Significant differences were found in ERβ expression between liver metastasis (P = 0.012) and CRC (P = 0.002) compared to adjacent normal tissues. Serum estrogen levels in patients with liver metastases were significantly lower than those without liver metastasis (P = 0.012).
BioAssay record AID 228035 submitted by ChEMBL: Inhibitory activity against Colchicine resistant parent primary liver carcinoma (PLC) cell line PLC/PRF/5.
TY - JOUR. T1 - Effect of the molar ratio of branched-chain to aromatic amino acids on growth and albumin mRNA expression of human liver cancer cell lines in a serum-free medium. AU - Saito, Y.. AU - Saito, H.. AU - Nakamura, M.. AU - Wakabayashi, K.. AU - Takagi, T.. AU - Ebinuma, H.. AU - Ishii, H.. PY - 2001/1/1. Y1 - 2001/1/1. N2 - Supplementation of branched-chain amino acids (BCAAs) is often used for the treatment of hepatic encephalopathy and low albuminemia in Japan. In this scenario, although many cases are complicated with hepatocellular carcinoma in chronic viral infection, the effect of BCAA levels on hepatocellular carcinoma cells remains unclear. We investigated the effect of the molar ratios of BCAAs to aromatic amino acids (AAAs) on the growth and albumin mRNA expression of cultured human liver cancer cell lines, HCC-M, HCC-T, PLC/PRF/5, and Hep G2. To exclude the effect of fetal serum in culture media on modification of the growth and albumin transcription of cell lines, we used ...
This multicentre, international, prospective observational study conducted in European centres plans to collect real-life data. This data will form an evidence-base from which conclusions can be drawn on how to improve patient selection and optimise treatment protocols when treating with TACE using …
Patients treated by liver resection had the best outcome, while patients with extrahepatic diseases had poor prognosis. The prognosis of patients treated by regional chemotherapy improved significantly with the advent of irinotecan and better selection.
The liver is an organ that develops primary and metastatic tumors. Hepatocellular carcinoma (HCC) is the fifth common type of cancer worldwide and the third leading cause of cancer death (1). The median survival is approximately 6 to 20 months after diagnosis for the intermediate and advanced stages, and the 5-year survival of patients with HCC is less than 30%. Even after apparently curative surgical resection, recurrent HCC develops in 80% of patients within 5 years because of intrahepatic metastasis. For unresectable HCC, different treatment modalities are available, including radiation, radioembolization, systemic chemotherapy, and molecularly targeted therapy. Oral sorafenib, which is a multityrosine kinase inhibitor, is currently the first-line treatment for advanced HCC but its effectiveness is limited (2). The liver is also a common site of metastasis from other solid tumors, especially tumors originating from the intra-abdominal organs, including the stomach, pancreas, colon, ...
TY - JOUR. T1 - Pathology of primary liver cancer. AU - Lapis, Károly. AU - Johannessen, Jan Vincents. PY - 1979/1/1. Y1 - 1979/1/1. N2 - After a brief survey of the factors that play a role in the etiopathogenesis of human hepatocellular carcinomas, a detailed description is given of the macroscopic and microscopic features of human liver cancers as well as their association with cirrhosis. The ultrastructural features of liver cancers of various degrees of differentiation are described. The mode of spread, metastasis formation of primary liver cancers, and most frequent causes of death of liver cancer patients are reviewed.. AB - After a brief survey of the factors that play a role in the etiopathogenesis of human hepatocellular carcinomas, a detailed description is given of the macroscopic and microscopic features of human liver cancers as well as their association with cirrhosis. The ultrastructural features of liver cancers of various degrees of differentiation are described. The mode of ...
CHICAGO -- Bevacizumab (Avastin) given before surgery for curative resection of liver metastases from colorectal cancer did not increase the risk of bleeding, researchers reported here.
A study released in the July 2016 issue of the American Journal of Roentgenology found that biphenotypic primary liver carcinoma may be misclassified as hepatocellular carcinoma.
Background After surgical resection of hepatocellular carcinoma (HCC), recurrence is common, especially in patients presenting with vascular invasion or multifocal disease after curative surgery. Consequently, we examined the expression pattern and prognostic value of miR-19b in samples from these patients. Methods We performed a miRNA microarray to detect differential expression of microRNAs (miRNAs) in 5 paired samples of HCC and non-tumoral adjacent liver tissue and a quantitative real-time polymerase chain reaction (PCR) analysis to validate the results in 81 paired samples of HCC and adjacent non-tumoral liver tissues. We examined the associations of miR-19b expression with clinicopathological parameters and survival. MiR-19b was knocked down in Hep3B and an mRNA microarray was performed to detect the affected genes. Results In both the miRNA microarray and real-time PCR, miR-19b was significantly overexpressed in the HCC tumor compared with adjacent non-tumor liver tissues (P < 0.001). The ...
Background After surgical resection of hepatocellular carcinoma (HCC), recurrence is common, especially in patients presenting with vascular invasion or multifocal disease after curative surgery. Consequently, we examined the expression pattern and prognostic value of miR-19b in samples from these patients. Methods We performed a miRNA microarray to detect differential expression of microRNAs (miRNAs) in 5 paired samples of HCC and non-tumoral adjacent liver tissue and a quantitative real-time polymerase chain reaction (PCR) analysis to validate the results in 81 paired samples of HCC and adjacent non-tumoral liver tissues. We examined the associations of miR-19b expression with clinicopathological parameters and survival. MiR-19b was knocked down in Hep3B and an mRNA microarray was performed to detect the affected genes. Results In both the miRNA microarray and real-time PCR, miR-19b was significantly overexpressed in the HCC tumor compared with adjacent non-tumor liver tissues (P < 0.001). The ...
Melanomul conjunctival Melanomul conjunctival este foarte rar. Pot exista motive ereditare pentru renașterea lor. Melanomul în iris apare în partea din față, partea colorată a ochiului.
Radioembolization (RE) is an emerging treatment strategy for patients with primary hepatic malignancies and metastatic liver disease. Though RE is primarily performed in the palliative setting, a shift toward the curative setting is seen. Currently, hepatic resection and in selected cases liver transplantation are the only curative options for patients ... read more with a hepatic malignancy. Unfortunately, at diagnosis most patients are not eligible for liver surgery due to the imbalance between the necessary liver resection and the remaining liver remnant. However, in borderline resectable cases, tumor volume reduction and/or increasing the future liver remnant can lead to a resectable situation. The combination of selective tumor treatment, the induction of hypertrophy of untreated liver segments, and its favourable toxicity profile make RE an appealing strategy for downstaging. The present review discusses the possibilities for RE in the preoperative setting as a downstaging tool or as a ...
Dr Philippa Matthews and colleagues review the associations between liver cancer risk and co-morbidities and other metabolic factors in individuals with chronic hepatitis B virus infection.
Metastatic liver cancer occurs due to the spreading of a primary cancer to the liver. Though incurable, you can try various treatment measures to get relief.
Background Age-adjusted liver cancer mortality rates have been increasing for both men and women in Japan since 1970 ; however, increases in mortality rates in men are much greater than those in women. Hepatitis C virus infections and heavy alcohol consumption are considered to be the major risk factors of liver cancer deaths in Japanese. The...
Featured Article: Phase II Trial of Hepatic Artery Infusional and Systemic Chemotherapy for Patients With Unresectable Hepatic Metastases From Colorectal Cancer: Conversion to Resection and Long-term Outcomes. Dangelica MI, Correa-Gallego C, Paty PB, et al. Ann Surg. 2014 Mar 21. [Epub ahead of print]. Summary: The rate of conversion of unresectable colorectal liver metastases (CRLM) to resectable CRLM has improved with modern systemic chemotherapy and biologic therapy. Results of recent studies, including randomized trials, report conversion rates of 20-38%. The combination of hepatic artery infusional (HAI) chemotherapy with systemic chemotherapy has become an attractive option for the treatment of unresectable CRLM owing to the high response rates observed in previous published studies.. This prospective phase II trial aimed to evaluate, as a primary endpoint, the conversion rate to complete resection (resectability rate) in patients with unresectable CRLM treated with HAI fluorodeoxyuridine ...
REFERENCES 1 Landis SH, Murray T, Bolden S, et al. Cancer Statistics. CA Cancer J Clin. 1999;49:8-31. 2 American Cancer Society.Cancer Facts & Figures, 2013.Atlanta, ACS, 2013:5. 3 Seidensticker R, Denecke T, Kraus P, et al. Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc Intervent Radiol. 2011 July 29. [Epub ahead of print] 4 Jakobs TF, Hoffman RT, Dehm K, et al. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J Vasc Interv Radiol. 2008;19(8):1187-1195. 5 Gray B, van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12(12):1711-1720. 6 van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus ...
The latest liver cancer risk factors statistics for the UK for Health Professionals. See data for factors associated with increased risk, decreased or no risk and more.
HONGFU, Liu et al. The Role and Significance of Bcl-2 and Bax in the Hepatic Carcinoma. Int. J. Morphol. [online]. 2012, vol.30, n.4, pp.1466-1473. ISSN 0717-9502. http://dx.doi.org/10.4067/S0717-95022012000400032.. This study aimed to observe the regularity of liver cell apoptosis and expression of apoptosis related gene Bcl-2 and Bax in the induced cancer, and explore the relationship between apoptosis and the development of liver cancer. In this study, 84 rats were used, 72 rats as experimental group induced by drinking water containing DEN, 12 rats as control group (CG). After laparotomy, the form, color, texture of the liver and metastatic tumor in both control and experimental groups were observed and recorded. The metastatic tumor and the liver tissue were sectioned and stained with hematoxylin-eosin staining to demonstrate the characteristic in morphological changes, the Hoechst 33342 fluorescent staining was applied to show and count the rate of apoptotic cell, and the in situ ...
BACKGROUND: Colorectal cancer (CRC) patients with metastatic disease can become cured if neoadjuvant treatment can enable a resection. The search for predictive biomarkers is often performed on primary tumours tissue. In order to assess the effectiveness of tailored treatment in regard to the primary tumour the differences in the genomic profile needs to be clarified.. METHODS: Fresh-frozen tissue from primary tumours, synchronous liver metastases and adjacent normal liver was collected from 21 patients and analysed by whole-exome sequencing on the Illumina HiSeq 2500 platform. Gene variants designated as damaging or potentially damaging by Ingenuity software were used for the subsequent comparative analysis. BAM files were used as the input for the analysis of CNAs using NEXUS software.. RESULTS: Shared mutations between the primary tumours and the synchronous liver metastases varied from 50 to 96%. Mutations in APC, KRAS, NRAS, TP53 or BRAF were concordant between the primary tumours and ...
Despite the use of alternative therapy strategies surgical resection of colorectal liver metastases remains the treatment of choice and is associated with long-term survival in a significant number of patients [1, 2]. After curative resection of colorectal liver metastases the 5-year survival rate ranges from 20% to 51% depending on preoperative selection criteria and published series [3]. However, up to 75% of resected patients will develop extra- or intrahepatic tumor recurrence [4]. One possible cause for this tumor recurrence may be intraoperative hematogenous tumor cell dissemination due to mechanical manipulation of the tumor during hepatic resection [5].. Recently, RT-PCR based protocols were developed for the detection of disseminated tumor cells [6]. We developed a sensitive and specific CK 20 RT-PCR system for detection of disseminated colorectal cancer cells in blood, bone marrow and lymph nodes [7-9]. By using the CK 20 RT-PCR, we demonstrated that there is a significantly enhanced ...
TY - JOUR. T1 - Expanding the role of surgical therapy for colorectal liver metastases. AU - Choti, Michael A.. PY - 2012/6. Y1 - 2012/6. N2 - Management of patients with colorectal metastases to the liver often requires complex multidisciplinary care. Improved short-term and long-term outcomes with hepatic resection have resulted in an increasing aggressive surgical approach for many of these patients. Even with more contemporary definition of resectability, however, most patients may not be initial candidates for resection. The use of other preoperative systemic and liver-directed therapies offers the opportunity to expand the number of patients who may be candidates for curative-intent strategies. Systemic therapies can achieve responses which are capable of downsizing unresectable disease to a resectable status. Local therapies can also be used in a similar way. Yet, the optimal application and timing of these multimodality approaches to expand the role of surgical therapy remain ...
Liver cancer is not common in the United States.. Liver cancer is the fourth most common cancer and the third leading cause of cancer death in the world. In the United States, men, especially Asian/Pacific Islander men, have an increased risk of liver cancer. The number of new cases of liver cancer and the number of deaths from liver cancer continue to increase, especially among middle-aged black, Hispanic, and white men. People are usually older than 40 years when they develop this cancer. Finding and treating liver cancer early may prevent death from liver cancer. Being infected with certain types of the hepatitis virus can cause hepatitis and increase the risk of liver cancer.. Hepatitis is most commonly caused by the hepatitis virus. Hepatitis is a disease that causes inflammation (swelling) of the liver. Damage to the liver from hepatitis that lasts a long time can increase the risk of liver cancer. There are six types of the hepatitis virus. Hepatitis A (HAV), hepatitis B (HBV), and ...
For more than 20 years, BroadcastMed has been innovating digital strategies for healthcare organizations. The company was first in the world to broadcast live surgeries on the internet using its ORLive solution which provides an intimate look inside the operating room.. ...
On World Cancer Day, the World Hepatitis Alliance is calling for the establishment of comprehensive hepatitis strategies to help prevent the 800,000 liver cancer deaths each year.. London, 4 February 2016 Rock-icon David Bowie died recently at the age of 69 after a battle with what is being reported as liver cancer. Each year, globally, more than 800,000 people die from liver cancer, the second biggest cancer killer.i Yet, a high majority of these deaths are completely preventable.. Liver cancer comes in two forms: primary liver cancer, where it begins in the liver, and secondary, where it spreads from other organs. Primary liver cancer, the most prevalent liver cancer worldwide, can be attributed to heavy drinking and other unhealthy lifestyle choices, but is most commonly caused by having a long-term infection with the hepatitis B or hepatitis C virus - which in turn accounts for the biggest cause of the 642,500 liver cancer related deaths per year, globally.i. What many people dont realise ...
Digital Liver Cancer Summit 2021: New follow-up data from a landmark study of liver cancer patients treated with a combination of an immunotherapy drug (atezolizumab) and a monoclonal antibody (bevacizumab) has shown the longest-ever survival time in a frontline phase 3 trial of systemic therapy in advanced hepatocellular carcinoma (HCC), demonstrating a major breakthrough in the field. The IMbrave150 trial found median overall survival was 19.2 months in patients treated with atezo+bev vs 13.4 months for those treated with sorafenib alone, the current standard treatment (HR, 0.66 [95% CI, 0.52-0.85]; P=0.0009). Survival at 18 months was 52% with atezo+bev and 40% in patients treated with sorafenib.. All patients in the trial had nonresectable HCC - the most common form of liver cancer - and had not previously been treated with systemic therapy. A total of 501 patients were treated in the multicentre, open label, randomised controlled trial and the new follow-up figures confirm the superiority ...
Although variable prognostic factors (patient age, number and size of metastases, lymph node infiltration, stage of primary disease, prior local recurrence of the primary tumor, and clear resection margin of metastatic lesion) have been suggested in some reports, many authors describe the importance of hormone receptor status as a prognostic factor for the primary tumor after complete resection of BCLM [12,17,20]. Golse and Adam [23] suggested that the best results after the resection of BCLM are achieved after applying selection criteria based on small metastases (, 4-5 cm), minor hepatectomy, radical resection (ideally R0, or R1), stable disease after neoadjuvant therapy, and a delay between primary and secondary lesions longer than 1 or 2 years. Howerver, the age of the patient, her hormone receptor status, and HER2 overexpression are not strong predictors of overall survival [23]. In our study, time to recurrence was relatively short if the metastatic lesion was larger than 5 cm, or there ...
October is Liver Cancer Awareness Month. It may be a sleeper of a event when compared to other health campaigns, but for us who live with viral hepatitis, its an uncomfortable but critical reminder of the importance of monitoring our liver health to prevent cancer.. Viral hepatitis, especially B and C, are viral infections that can cause liver cancer (also called hepatocellular carcinoma or HCC.) Researchers are still studying why some people are more prone to liver cancer, but we who live with chronic hepatitis B or C have a 25 to 40 percent lifetime risk of developing liver cancer. The infection, which hijacks our liver cells to manufacture more virus, causes inflammation, scarring and even cancer as the liver cells grow out of control.. The longer we are infected with viral hepatitis, the higher our risk of developing liver cancer. While liver cancer often occurs in people with cirrhosis (severe liver scarring), some of us develop cancer without cirrhosis.. Liver cancer is also a threat to ...
05 Oct 2017. A new article published by JAMA Oncology reports the results of the Global Burden of Disease 2015 study on primary liver cancer incidence, death and years of healthy life lost in 195 countries or territories from 1990 to 2015.. Liver cancer is among the leading causes of cancer death worldwide.. The article by the Global Burden of Disease Liver Cancer Collaboration and corresponding author Christina Fitzmaurice, M.D., M.P.H., of the University of Washington, Seattle, estimates there were 854,000 new cases of liver cancer and 810,000 deaths globally in 2015.. Cases of incident (new) liver cancer increased 75 percent between 1990 and 2015, which was mostly explained by population aging and population growth, according to the authors.. In 2015, hepatitis B virus was the leading cause of new cases of liver cancer, deaths and disability-adjusted life-years (DALYS), which is the sum of years of life lost and years lived with disability such that one DALY can be interpreted as one lost ...
Advances in surgical fields and chemotherapy regimens have been increasing long-term outcomes for patients with Colorectal Liver Metastases (CRLM). The liver resection re..
The liver acts as a hub for metabolic reactions to keep a homeostatic balance during development and growth. The process of liver cancer development, although poorly understood, is related to different etiologic factors like toxins, alcohol, or viral infection. At the molecular level, liver cancer is characterized by a disruption of cell cycle regulation through many molecular mechanisms. In this review, we focus on the mechanisms underlying the lack of regulation of the cell cycle during liver cancer, focusing mainly on hepatocellular carcinoma (HCC). We also provide a brief summary of novel therapies connected to cell cycle regulation.
Hepatocellular carcinoma (HCC) is the second leading cause of cancer death worldwide and metastasis is regarded as the major cause of HCC-associated lethality. In this study, we have analysed the TCGA whole-transcriptome sequencing data of paired human HCC samples (n=50), and identified Forkhead Box M1 (FOXM1) and Centromere Protein F (CENPF) to be the top-listing upregulated genes. Interestingly, both of them are the essential components in cell-cycle progression. FOXM1 encodes for the cell-cycle-dependent transcription factor that regulates genes for DNA replication and mitosis, while CENPF encodes for the centromere protein that is required for kinetochore function and chromosome segregation in mitosis.. We hypothesized that the upregulation of FOXM1-CENPF signaling axis may drive hepatocarcinogenesis. In our human HCC cohort (n=34), FOXM1 and CENPF were shown to be upregulated compared with the non-tumorous liver tissues, and their mRNA expressions were positively correlated (p,0.0001). ...
Only a small amount of liver cancers are found early and can be totally removed by surgery. Less that 30 percent of patients are able to have their tumor totally removed. The overall five year survival rate for liver cancer is about 9 percent. One reason for this low number is that many patients with liver cancer have cirrhosis of the liver which could be fatal in itself.. The numbers do sound grim, but not necessarily what will happen, everyone is unique and this cancer can be treated. Surgery, chemotherapy and radiation are used to combat primary liver cancer. One way that liver cancer can be cured is by a liver transplant. This option is for those patients with small liver tumors whos cancer cannot be surgically removed. Over 2500 transplants were performed with people with liver cancer in the last two years. The good news is that the five year survival for these patients was 70 percent.. Some specific treatments available for liver cancer:. ...
Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC), both increasing in incidence, have become a major topic of basic and clinical research as well as clinical practice in hepatology. Experts in the field update the current concepts on the carcinogenesis of HCC and CC such as genetic alterations in the pathways of cell cylce and apoptosis regulation, the hypothesis of dedifferentiation of hepatocytes to the malignant phenotype vs that of activation of hepatic progenitor cells incapable of maturation (maturation arrest hypothesis). In spite of an increasing number of genetic alterations described in human HCC as well as cell regulatory pathways tested in experimental HCC models, the key hits causing progression of the cell cycle in imbalance with apoptosis, tissue invasive growth and metastatic potential of cell clones still remain elusive. Very powerful genomic and proteomic techniques are promising insights into the carcinogenesis of liver malignancies that will allow more efficient therapeutic
The aim of this study was to determine the effect of chemotherapy on the accuracy of CT scan for the preoperative evaluation of colorectal liver metastases (LM). Between 1999 and 2005, 92 patients wit
A minority of patients with colorectal liver metastases and hepatobiliary cancer (primary liver cancer) are candidates for surgery, but there are no curative treatment options for these patients. Their median survival time is 3 to 12 months. Stereotactic radiation (SRT) (highly conformal radiotherapy (CRT)) is a treatment option for these patients with unresectable liver cancer, now possible due to improvements in our ability to localize and immobilize liver tumors and an improved understanding of the partial liver volume tolerance to radiation. SRT should permit liver tumors to be treated to tumorcidal doses while sparing the uninvolved liver, decreasing the risk of treatment related normal tissue toxicity. With such conformal radiation, it is possible to deliver radiation in fewer fractions than traditionally required, which should be more convenient for patients. In this study, CRT will be delivered during shallow breathing or breath hold to minimize organ motion due to breathing, decreasing ...
Liver Cancer Treatment of Alternative Liver Cancer Alternative Neuro Acupuncture Treatment and Liver Cancer Herbal Herbs Alternative Medicine Treatment on Liver Cancer Treatment Medical Center Liver Cancer Remedies
US Pharm. 2016;41(12):HS-20.. Reoviruses, which cause childhood coughs and colds, could help in the fight against primary liver cancer, according to a study by University of Leeds researchers in England. The reovirus, say the scientists, is also able to kill the hepatitis C virus, which is a common cause of primary liver cancer and the third highest cause of cancer deaths worldwide.. Study coleader Dr. Stephen Griffin, associate professor of viral oncology at the University of Leeds, said, Ultimately we hope that by simultaneously treating the tumour, and the hepatitis virus that is driving the growth of the tumour, we may provide a more effective therapy and improve the outcomes for patients.. The University of Leeds team found that reovirus was successful against liver cancer cells grown in the laboratory as well as those collected from patients undergoing surgery. The study results were published in the journal Gut.. ...
Liver metastasis occurs when cancerous tumor cells spread to the liver from another part of the body. – A free PowerPoint PPT presentation (displayed as a Flash slide show) on PowerShow.com - id: 88e988-NzRlM
BMI, WC, and type II diabetes mellitus were associated with higher risks of liver cancer in this prospective analysis of 1.57 million participants enrolled in 14 U.S.-based cohort studies. Higher BMI was associated with liver cancer in a dose-response manner, and associations were robust after controlling for smoking, alcohol intake, and other risk factors. High WC was associated with higher risks of liver cancer, and these associations were attenuated after including BMI in the statistical models, suggesting shared effects of both BMI and WC on liver cancer risk, perhaps owing to these phenotypes being correlated with visceral adiposity. Type II diabetes mellitus was a strong predictor of liver cancer risk, and these results were robust even at nonobese BMI levels and after controlling for their shared risk factors. Some evidence of heterogeneity was detected across studies when sensitivity analyses were conducted in individual participant meta-analyses, which seemed to be the result of our ...
Dublin, May 17, 2021 (GLOBE NEWSWIRE) -- The Global Liver Cancer Hepatoma Epidemiology and Patient Flow - 2021 report has been added to ResearchAndMarkets.coms offering. Global Liver Cancer Hepatoma Epidemiology and Patient Flow Analysis - 2021, provides Liver Cancer Hepatoma epidemiology, demographics, and patient flow. The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.The research provides population data to characterize Liver Cancer Hepatoma patients, history of the disease at the population level (Liver Cancer Hepatoma prevalence, Liver Cancer Hepatoma incidence) and at the clinical level (from diagnosis to treated patients). It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.Research scope: Liver Cancer Hepatoma patient flow: Liver Cancer Hepatoma prevalence, diagnosed, and drug-treated patientsCountries: US, Germany, France, Italy, Spain, UK, Japan,
Research should document indications for treatment, details of patient selection and details of adjuvant and prior treatments. Outcome measures should include complications, survival and quality of life. Data from welldesigned trials comparing the procedure against other forms of management would be particularly useful, but prospective observational studies may also be of value ...
Pfizer is currently recruiting for the NCT00106054 Colorectal Neoplasms, Liver Neoplasms Cancer trial. Review trial description, criteria and location information here.
Even after a functional cure for hepatitis B is achieved, the risk for hepatocellular carcinoma persists in older patients, new research warns. Medscape Medical News
초록. Liver resection is the only curative treatment for patients with colorectal liver metastases (CLMs). Neoadjuvant chemotherapy can improve resectability but has a potential harmful effect on the nontumorous liver. Patients with chemotherapy-induced hepatic injury undergoing liver surgery have higher risks of post-resectional morbidity. We present two cases of patients without pre-existent liver disease treated with oxaliplatin-based chemotherapy followed by surgical resection of their CLMs. Their intra-operative liver specimen showed morphologic abnormalities characteristic of nodular regenerative hyperplasia (NRH). NRH led to portal hypertension in both patients that resulted in deleterious post-resectional complications and death of one patient. Interestingly, the other patient underwent two repeat nonanatomic liver resections because of recurrent CLMs. The intra-operative liver specimen still showed signs of NRH and sinusoidal congestion, but the post-resectional courses were ...
Fibrolamellar hepatocellular carcinoma (FLC) is a rare subtype of primary liver cancer. Fibrolamellar hepatocellular carcinoma was first described Edmondson in 1956.[1][2] Fibrolamellar hepatocellular carcinoma is most commonly seen in children and young adults. The pathogenesis of fibrolamellar hepatocellular carcinoma is characterized by the lack of cirrhosis. Common causes of fibrolamellar hepatocellular carcinoma, include: active hepatic inflammation, hepatitis B or C viral infection, alcohol-related liver disease, nonalcoholic fatty liver disease, and dietary aflatoxin B1. The majority of patients with fibrolamellar hepatocellular carcinoma remain asymptomatic for years. Early clinical features include abdominal pain, weight loss, and malaise. If left untreated, the majority of patients with fibrolamellar hepatocellular carcinoma may progress to develop metastasis to abdominal lymph nodes, peritoneum, and lung. Common complications of fibrolamellar hepatocellular carcinoma include: hepatic ...
Headline: Bitcoin & Blockchain Searches Exceed Trump! Blockchain Stocks Are Next!. Metastatic Hepatocellular Carcinoma (HCC) market report covers research informatics related to Metastatic Hepatocellular Carcinoma (HCC) clinical trials, such as a listing of industry and sponsored clinical trials as well as new drug therapies.. Designed to be a resource both for patients interested in participating in Metastatic Hepatocellular Carcinoma (HCC) clinical trials and for research professionals.. The report, Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016″ provides an overview of Metastatic Hepatocellular Carcinoma (HCC) clinical trials scenario. This report provides top line data relating to the clinical trials on Metastatic Hepatocellular Carcinoma (HCC). Report includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), ...
TY - JOUR. T1 - First-time use of bevacizumab for aggressive, metastatic hepatocellular carcinoma in an HIV/hepatitis B virus coinfected patient. T2 - A case report. AU - Baraboutis, Ioannis G.. AU - Papastamopoulos, Vassilios. AU - Charitsis, Georgios. AU - Lekakis, Lazaros J.. AU - Vaslamatzis, Michael M.. AU - Skoutelis, Athanasios T.. PY - 2008/5/1. Y1 - 2008/5/1. N2 - We present a case of an HIV-1 infected patient with history of chronic hepatitis B and chronic alcohol use without cirrhosis, who presented with aggressive hepatocellular carcinoma with multiple metastases. Systemic chemotherapy combined with use of bevacizumab (anti-vascular endothelium growth factor monoclonal antibody) was without effect and the patient succumbed to his disease within few weeks. To our knowledge, this is the first report in the English literature of bevacizumab use for metastatic hepatocellular carcinoma in HIV-infected patients.. AB - We present a case of an HIV-1 infected patient with history of chronic ...
BACKGROUND AND AIM: Patients with persistently active hepatitis B virus (HBV) replication are at high risk for progression to liver cirrhosis and hepatocellular carcinoma (HCC). The influence of the viral load of HBV on intrahepatic recurrence after local ablation therapy in patients with HBV-related HCC has not been elucidated. We aimed to evaluate predictors of intrahepatic recurrence and clarify the correlation between viral load and intrahepatic recurrence after percutaneous ablation.. METHODS: Patients with HBV-related, solitary HCC undergoing radiofrequency ablation (RFA) or percutaneous ethanol injection (PEI), between October 2004 and December 2008 were prospectively enrolled. Statistical analyses were performed using the Kaplan-Meier method and Cox regression model to identify risk factors for intrahepatic recurrence.. RESULTS: A total of 145 patients (male, 81.4%; mean age, 55.3 years) were included. Ninety patients (62.1%) had serum HBV DNA ≥2000 IU/mL. The median follow-up duration ...
Gehring, A.J., Ho, Z.Z., Tan, A.T., Bertoletti, A., Aung, M.O., Lim, S.G., Lee, K.H., Tan, K.C., Lim, S.G. (2009). Profile of Tumor Antigen-Specific CD8 T Cells in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma. Gastroenterology 137 (2) : 682-690. [email protected] Repository. https://doi.org/10.1053/j.gastro.2009.04. ...
On May 29, 2020, the FDA approved the immunotherapy atezolizumab (Tecentriq; Genentech), a PD-L1 inhibitor, in combination with bevacizumab (Avastin; Genentech), a vascular endothelial growth factor inhibitor, for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received systemic therapy. This is the first immunotherapy regimen approved by the FDA for this type of HCC.
Fibrolamellar hepatocellular carcinoma (FHCC) is a rare form of hepatocellular carcinoma (HCC) that typically affects young adults and is characterized, under the microscope, by laminated fibrous layers interspersed between the tumour cells. Approximately 200 new cases are diagnosed worldwide each year. A recent study showed the presence of the DNAJB1-PRKACA chimeric transcript (resulting from a 400kb somatic deletion on chromosome 19) in 100% of the FHCCs examined (15/15) This gene fusion has been confirmed in a second study. The histopathology of FHCC is characterized by laminated fibrous layers, interspersed between the tumor cells. Cytologically, the tumor cells have a low nuclear to cytoplasmic ratio with abundant eosinophilic cytoplasm. Tumors are non-encapsulated, but well circumscribed, when compared to conventional HCC (which typically has an invasive border). Due to lack of symptoms, until the tumor is sizable, this form of cancer is often advanced when diagnosed. Symptoms include ...
TY - JOUR. T1 - Effects of MACC1 polymorphisms on hepatocellular carcinoma development and clinical characteristics. AU - Lin, Chien Hua. AU - Hsieh, Ming Ju. AU - Lee, Hsiang Lin. AU - Yang, Shun Fa. AU - Su, Shih Chi. AU - Lee, Wei Jiunn. AU - Chou, Ying Erh. PY - 2020/1/1. Y1 - 2020/1/1. N2 - Hepatocellular carcinoma (HCC) is a major malignancy of cancer-related mortality worldwide. Metastasis-associated in colon cancer-1 (MACC1) was suggested as a marker for vascular invasive HCC. This study investigated the MACC1 single-nucleotide polymorphisms (SNPs) to evaluate HCC susceptibility and clinicopathological characteristics. In this study, real-time polymerase chain reaction was applied to analyze five SNPs of MACC1 rs1990172, rs975263, rs3095007, rs4721888, and rs3735615 in 378 patients with HCC and 1199 cancer-free controls. The results showed that in 151 HCC patients among smokers who carried MACC1 rs1990172 CA + AA variants had a lower risk of developing a large tumor (odds ratio [OR] = ...
To the editor: We are writing in response to the letter (1) on fibrolamellar hepatocellular carcinoma, in which Ruffin points out that the cases of this tumor reported since 1941 have all originated in the United States. We report two cases of this tumor diagnosed in patients treated at our hospital.. A 25-year-old man was hospitalized for epigastric discomfort; anorexia was present for 5 months. Physical examination showed a liver edge 12 cm below the right costal margin. The erythrocyte sedimentation rate was 135 mm/h; alkaline phosphatase, 100 U/L (normal, ≤ 40 U/L); and gamma-glutamyltransferase, 89 IU/L (normal, ≤ 30 ...
Dynamic monitoring of serum alpha-fetoprotein and its correlation with early hepatocellular carcinoma in patients with chronic hepatitis B, Qing-Feng Chen, Xiao-Min Luo, Mei-Ping Z
TY - JOUR. T1 - A single institute retrospective trial of concurrent chemotherapy with SIR-Spheres® versus SIR-Spheres® alone in chemotherapyresistant colorectal cancer liver metastases. AU - Cho, May. AU - Kessler, Jonathan. AU - Park, John J.. AU - Lee, Aram. AU - Gong, Jun. AU - Singh, Gagandeep. AU - Chen, Yi Jen. AU - Ituarte, Philip H.G.. AU - Fakih, Marwan. PY - 2017/8/1. Y1 - 2017/8/1. N2 - Background: The use of selective internal radiation therapy with yttrium 90 resin microspheres (SIRSpheres ®) in chemotherapy-resistant colorectal cancer liver metastases has been associated with favorable progression-free survival (PFS) and overall survival when given alone or concurrently with chemotherapy. We conducted a single institute retrospective trial to explore the potential impact of SIR-Spheres® with concurrent chemotherapy vs. SIR-Spheres® alone on liver PFS in patients with colorectal liver metastases (CRLM). Methods: Patients with 5-fluorouracil-refractory CRLM treated with ...
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
HCC is the third most common cancer worldwide, causing about 700,000 deaths annually.2 It is associated with cirrhosis, hepatitis B and C virus, primary biliary and sclerosing cholangitis, aflatoxins, and autoimmune hepatitis.2,3 Extrahepatic metastatic HCC, as observed in this case, occur in 30-50% of HCC patients; the most common sites are lungs, bones, adrenal glands, and lymph nodes.4 Rare and unusual metastatic sites have been described in the literature, including the chest wall presenting as a breast mass and metastasis to the nasal septum.5,6 Indeed, extrahepatic metastases to the humeral shoulder, chest wall, and bony lesions are exceedingly rare, as only a handful of cases have been reported.3,7 Traditionally, a few systems have been widely employed for HCC staging (e.g. Okuda, tumor/node/metastasis), however, newer classification systems that take into account prognostication and treatment regimens are increasingly being utilized.8 The Cancer of the Liver Italian Program (CLIP) and ...
RESULTS: Seven patients (median age 21 years, range 19 - 42, 5 men, 2 women) underwent surgery for FLC. No patient had underlying liver disease or an elevated alpha feto-protein (AFP) at either initial presentation or recurrence. Six patients had a solitary tumour at diagnosis (mean largest diameter = 12cm), and underwent left hepatectomy (N=2), right hepatectomy (N=1), extended right hepatectomy (N=1), and segmentectomies (N=2). Three patients underwent a portal lymphadenectomy for regional lymphatic tumour involvement. One patient with advanced extrahepatic portal nodal metastasis was unresectable. No peri-operative deaths occurred. Recurrence occurred post resection in all 6 patients. Median overall survival was 60 months, and overall 5-year survival was 4 out of 7 (57%). Post-resection survival (N=6) was 61 months, with a 5-year survival rate of 4 out of 6 (67%). The patient with unresectable disease survived 38 months after tumour embolisation with Lipiodol ...
Two firsts in studies of colorectal liver metastases were highlighted at the 2015 ASCO Annual Meeting: the first prospective randomized trial to evaluate radiofrequency ablation plus chemotherapy1 and the first large randomized phase III trial to study liver-directed selective internal radiation therapy.2 Radiofrequency ablation plus chemotherapy appeared to have clear benefit in this setting, whereas the results for selective internal radiotherapy in first-line therapy are currently less conclusive. Daniel G. Haller, MD, of Abramson Cancer Center at the University of Pennsylvania, discussed both trials at Best of ASCO® 2015 in Boston.. Radiofrequency Ablation Plus Chemotherapy. Unresectable liver metastases treated with radiofrequency ablation plus chemotherapy improved long-term overall and progression-free survival compared with chemotherapy alone in patients with metastatic colorectal cancer, according to the results of the randomized phase II study of the EORTC NCRI CCSG-ALM Intergroup ...
TY - JOUR. T1 - Risk factors for early recurrence after curative hepatectomy for colorectal liver metastases. AU - Yamashita, Yo Ichi. AU - Adachi, Eisuke. AU - Toh, Yasushi. AU - Ohgaki, Kippei. AU - Ikeda, Osamu. AU - Oki, Eiji. AU - Minami, Kazuhito. AU - Sakaguchi, Yoshihisa. AU - Tsujita, Eiji. AU - Okamura, Takeshi. PY - 2011/4/1. Y1 - 2011/4/1. N2 - Purpose. With the broadening indications for hepatectomy to treat colorectal liver metastases (CRLM), early recurrence is a major problem. The aim of this study is to identify risk factors of early recurrence, defi ned as recurrence within 1 year after surgery. Methods. A retrospective analysis was performed on 121 consecutive patients who underwent hepatectomy for CRLM. Results. Among 121 patients, 52 (43.0%) developed early recurrence. The independent risk factor for early recurrence was number of liver metastases ≥3 (odds ratio 2.65). There were signifi cantly more patients with liver recurrence (51.9%) and recurrence beyond curative ...
Many chemotherapeutic agents have been successfully used to treat hepatocellular carcinoma (HCC);however, the development of chemoresistance in liver cancer cells usually results in a relapse and worseningof prognosis. It has been demonstrated that DNA methylation and histone modification play crucial roles inchemotherapy resistance. Currently, extensive research has shown that there is another potential mechanismof gene expression control, which is mediated through the function of short noncoding RNAs, especially formicroRNAs (miRNAs), but little is known about their roles in cancer cell drug resistance. In present study, bytaking advantage of miRNA effects on the resistance of human hepatocellular carcinoma cells line to cisplatin, ithas been demonstrated that miR-340 were significantly downregulated whereas Nrf2 was upregulated in HepG2/CDDP (cisplatin) cells, compared with parental HepG2 cells. Bioinformatics analysis and luciferase assays ofNrf2-3-untranslated region-based reporter constructor
Hepatitis C virus (HCV) infection causes chronic hepatitis, which can progress to cirrhosis and hepatocellular carcinoma (HCC). The incidence of hepatocellular carcinoma in the United States tripled between 1975 and 2005, and is expected to increase further, and to remain elevated for more than 20 years. Curing hepatitis C infection in patients with cirrhosis through treatment with peginterferon and ribavirin reduces the risk of developing hepatocellular carcinoma. Several noncurative treatments also appear to reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Prospective studies report a reduced incidence of hepatocellular carcinoma among patients treated with a mixture of carotenoids with or without myo-inositol, with vitamin K(2), or with polyprenoic acid (an acyclic retinoid). Uncontrolled and/or retrospective studies have reported beneficial effects of treatment with Sho-saiko-to, glycyrrhizin and ursodeoxycholic acid on hepatocellular carcinoma incidence. ...
TY - JOUR. T1 - Teroxirone suppresses growth and motility of human hepatocellular carcinoma cells. AU - Kim, Seung Hun. AU - Wang, Wen Hsing. AU - Wang, Jing Ping. AU - Hsieh, Chang Heng. AU - Fang, Kang. PY - 2018/3. Y1 - 2018/3. N2 - Aims: The prevalent human hepatocellular carcinoma (HCC) is a leading cause of global cancer-related mortality. The small molecular weight triepoxide derivative, 1,3,5-triazine-2,4,6(1H,3H,5H)-tri-one-1,3,5-tri-(oxiranylmethyl) (teroxirone), has been proved effective against the proliferation of lung cancer cells. The purpose is to further examine if teroxirone regulate growth and metastatic potential of HCC cells with aims at disclosing more of the reaction mechanisms. Main methods: Measurements of cell viability and flow cytometry were conducted to test sensitivities of teroxirone against HCC cells. The signaling pathway leading to apoptotic death was unraveled by Western blotting analysis. The metastatic progression was evaluated by cell-based phenotype assay ...
Neovascularization provides the route for nutrient supply to the tumor and the conduit for tumor cells to be shed into the circulation. CD31 is a pan-endothelial cell marker and CD105 is an active endothelial cell marker, but whether there is a link between CD105 expression and metastasis in Hepatocellular carcinoma (HCC) still remains unclear. A tissue microarray containing 38 HCCs and adjacent non-tumorous liver tissue samples was constructed. The microvessel density (MVD) of CD31, CD105, vWF and the expression of PCNA, VEGF were investigated in a HCC tissue microarray by immunohistochemistry. There was a significant difference between the score of MVD-CD31 in HCC (48.5 ± 29.7) and non-tumorous liver tissue (24.2 ± 22.3, P|0.01). The mean score of MVD-CD31 was higher in HCCs with high PCNA expression (68.4 ± 37.0) than in HCCs with low PCNA expression (37.9 ± 30.9, P = 0.012). MVD-CD105 and VEGF expression were significantly higher in HCC with intrahepatic metastasis (P | 0.01). Multivariate
TY - JOUR. T1 - Recurrent hepatocellular carcinoma after liver transplant. T2 - Identifying the high-risk patient. AU - Nissen, Nicholas N.. AU - Menon, Vijay. AU - Bresee, Catherine. AU - Tran, Tram T.. AU - Annamalai, Alagappan. AU - Poordad, Fred. AU - Fair, Jeffrey H.. AU - Klein, Andrew S.. AU - Boland, Brendan. AU - Colquhoun, Steven D. PY - 2011/1/1. Y1 - 2011/1/1. N2 - Background: Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) is rarely curable. However, in view of the advent of new treatments, it is critical that patients at high risk for recurrence are identified. Methods: Patients undergoing LT for HCC at a single centre between 2002 and 2010 were reviewed and data on clinical parameters and explant pathology were analysed to determine factors associated with HCC recurrence. All necrotic and viable tumour nodules were included in explant staging. All patients underwent LT according to the United Network for Organ Sharing (UNOS) Model for End-stage Liver ...
In the present study, serotonin 2C (5-HT2c) receptor binding parameters in the brainstem and cerebral cortex were investigated during liver generation after partial hepatectomy (PH) and N-nitrosodiethylamine (NDEA) induced hepatic neoplasia in male Wistar rats. The serotonin content increased significantly (p,0.01) in the cerebral cortex after PH and in NDEA induced hepatic neoplasia. Brain stem serotonin content increased significantly (p,0.05) after PH and (p,0.001) in NDEA induced hepatic neoplasia. The number and affinity of the 5-HT2c receptors in the crude synaptic membrane preparations of the brain stem showed a significant (p,0.001) increase after PH and in NDEA induced hepatic neoplasia. The number and affinity of 5-HT2c receptors increased significantly (p,0.001) in NDEA induced hepatic neoplasia in the crude synaptic membrane preparations of the cerebral cortex. There was a significant (p,0.01) increase in plasma norepinephrine in PH and (p,0.001) in NDEA induced hepatic neoplasia, ...
It has been estimated that 70% to 90% of patients with hepatocellular carcinomas have an established background of chronic liver disease or cirrhosis, the major causes of which are HBV or HCV infection (26, 27). More than 50% (340,000 cases) of all hepatocellular carcinomas worldwide are associated with HBV infection and near 30% (195,000 cases) are HCV infection-related (28, 29). Once cirrhosis is established, the annual risk of developing hepatocellular carcinoma is estimated to be as high as 3% to 4% (30). Screening for hepatocellular carcinoma using serum AFP or combined with ultrasonography in these high-risk populations is still the essential way for detection and diagnosis of hepatocellular carcinomas at an earlier stage, when curative therapies are likely to be more successful (31, 32).. On the basis of the specific screening requirements for hepatocellular carcinomas in the context of chronic liver disease and cirrhosis and the general criteria for an adequate screening test to detect ...
Reference list:. Moulton C-A, Gu C-S, Law CH, Tandan VR, Hart R, Quan D, et al. Effect of PET Before Liver Resection on Surgical Management for Colorectal Adenocarcinoma Metastases: A Randomized Clinical Trial. JAMA. 2014;311(18):1863-9.. Bahadoer RR, Dijkstra EA, Etten B van, Marijnen CAM, Putter H, Kranenbarg EM-K, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):29-42.. ...
TY - JOUR. T1 - Lipocalin-2 Induces Apoptosis in Human Hepatocellular Carcinoma Cells Through Activation of Mitochondria Pathways. AU - Chien, Ming Hsien. AU - Ying, Tsung Ho. AU - Yang, Shun Fa. AU - Yu, Ji Kuen. AU - Hsu, Chih Wei. AU - Hsieh, Shu Ching. AU - Hsieh, Yi Hsien. PY - 2012. Y1 - 2012. N2 - Lipocalin 2 (LCN2) is a secreted, iron-binding glycoprotein that is abnormally expressed in some malignant human cancers. However, the roles of LCN2 in hepatocellular carcinoma (HCC) cells are unknown. In this study, we suggested the LCN2 and LCN2R were weak detected in the HCC cell lines, LCN2 and LCN2R were found to be down-regulated in tumor tissues in 16 HCC patients. MTT, DAPI, TUNEL, and flow cytometry analyses revealed that LCN2 overexpression dramatically inhibited cell viability, induced apoptosis features of cell-cycle arrest in sub-G1 phase, in DNA fragmentation, and in condensation of chromatin in Huh-7 and SK-Hep-1 cells. Western blots were used to detect the activation of caspase, ...
Gentaur molecular products has all kinds of products like :search , US Biomax \ Hepatocellular carcinoma tissue array, 63 cases_63 cores, replaced by LV809 \ BS03014 for more molecular products just contact us
The liver is the most common anatomical site for hematogenous metastases from colorectal cancer. Therefore effective treatment of liver metastases is one of the most challenging elements in the management of colorectal cancer. However, there is rare available clinical consensus or guideline only focusing on colorectal liver metastases. After six rounds of discussion by 195 clinical experts of the Shanghai International Consensus Expert Group on Colorectal Liver Metastases (SINCE) from 29 countries or regions, the Shanghai Consensus has been finally completed, based on current research and expert experience. The consensus emphasized the principle of multidisciplinary team, provided detailed diagnosis approaches, and guided precise local and systemic treatments. This Shanghai Consensus might be of great significance to standardized diagnosis and treatment of colorectal liver metastases all over the world.
Purpose: Early recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) carries a poor prognosis. We aimed to develop a risk score for early HCC recurrence using pre-LT variables.. *Methods: Adults undergoing LT for HCC from 2001-2015 from 6 large centers were reviewed. Competing risk regression was used to identify predictors of early HCC recurrence (≤ 1 year).. *Results: Of 3235 patients, 459 developed HCC recurrence (14.2%), including 175 (38%) recurrences within 1 year of LT. Independent pre-LT predictors of early HCC recurrence included initial tumor size > 3 cm, ≥ 3 pre-LT locoregional therapies, pre-LT neutrophil-to-lymphoycte ratio > 5, and alpha-fetoprotein response. The early recurrence risk score was created using hazard ratios and resulted in low (0 points), low-medium (2-4 points), medium-high (5-8 points), and high (>8 points) risk groups (Fig 1). The probability of recurrence at 1-year in the low-risk group was 1.8% vs. 44.9% in the high-risk group ( ...
To evaluate the clinical efficacy of interferon-α in hepatocellular carcinoma, 71 adult Chinese patients with histologically proven inoperable hepatocellular carcinoma were randomized to receive recombinant interferon- α(2a) (50 x 106 IU/m2) intramuscularly three times a week (n = 35) or no antitumor therapy (n = 36). The survival of interferon-α-treated patients was significantly better than that of patients who received no antitumor therapy (p = 0.0471); median lengths of survival were 14.5 and 7.5 wk, respectively. Objective tumor regression greater than 50% was observed in 31.4% (11 of 35) of patients receiving interferon-α. Interferon-α induced tumor regression greater than 50% in 11 (31.4%) patients. Compared with the group receiving no antitumor therapy, the interferon-α therapy group had more tumor regression (p < 0.0001) and less tumor progression (p = 0.001). This high-dose interferon-α therapy was relatively well tolerated; only 34.3% of patients required reduction of dosage by ...
JNK proteins have been shown to be involved in liver carcinogenesis in mice, but the extent of their involvement in the development of human liver cancers is unknown. Here, we show that activation of JNK1 but not JNK2 was increased in human primary hepatocellular carcinomas (HCCs). Further, JNK1 was required for human HCC cell proliferation in vitro and tumorigenesis after xenotransplantation. Importantly, mice lacking JNK1 displayed decreased tumor cell proliferation in a mouse model of liver carcinogenesis and decreased hepatocyte proliferation in a mouse model of liver regeneration. In both cases, impaired proliferation was caused by increased expression of p21, a cell-cycle inhibitor, and reduced expression of c-Myc, a negative regulator of p21. Genetic inactivation of p21 in JNK1-/- mice restored hepatocyte proliferation in models of both liver carcinogenesis and liver regeneration, and overexpression of c-Myc increased proliferation of JNK1-/- liver cells. Similarly, JNK1 was found to control the
Sigma-Aldrich offers abstracts and full-text articles by [Gek San Tan, Kiat Hon Lim, Hwee Tong Tan, May Lee Khoo, Sze Huey Tan, Han Chong Toh, Maxey Ching Ming Chung].
TY - JOUR. T1 - Treatment strategies for locally advanced rectal cancer with synchronous resectable liver metastasis. AU - Park, Youn Young. AU - Kim, Namkyu. PY - 2018/1/1. Y1 - 2018/1/1. N2 - Approximately one-third of patients with colorectal cancer are estimated to be diagnosed with synchronous liver metastasis (LM). The only method to get cured is to achieve curative resection for both primary and LM. When it comes to locally advanced rectal cancer with synchronous LM, determination of the treatment strategy for each individual is a quite complex procedure, because it demands sophisticated consideration for both local and systemic control. Timing for the application of systemic chemotherapy (CTx), determination of a chemotherapeutic agent, radiation dose and fractions, and sequencing of preoperative treatment and surgeries are all essential components for establishing optimal treatment strategies for the patients with this disease. In this article, treatment strategies proposed in the ...
Cell culture. Human hepatocellular carcinoma cell line (Hep3B), human colorectal carcinoma cell line (SW620), and human normal lung fibroblast cell lines (NHLF and MRC5) were obtained from the American Type Culture Collection. Human hepatocellular carcinoma cell lines (BEL7404 and SMMC7721) and human normal liver cell lines (QSG7701 and L-02) were purchased from the Shanghai Cell Collection. HEK293 was obtained from Microbix Biosystems, Inc. Cells were maintained in humidified 37°C atmosphere containing 5% CO2 and cultured in DMEM (Life Technologies) supplemented with 10% heat-inactivated fetal bovine serum (Life Technologies), 4 mmol/L glutamine, 50 units/mL penicillin, and 50 μg/mL streptomycin.. Virus construction and production. The constructs including pCN205-EGFP and pCN205-IL-24 were generated according to the standard molecular cloning protocol. The homologous recombination between pCN205-EGFP and pCN205-IL-24 plasmids and pCN103 plasmid carrying oncolytic adenoviral backbone was done ...
CD80 transfected human hepatocellular carcinoma cells activate cytotoxic T lymphocytes to target HCC cells with shared tumor antigens
Currently in Japan, HCV infection is the most common background liver disease of HCC, followed by HBV infection and alcoholic liver disease. Primary biliary cirrhosis and other chronic liver diseases are an uncommon cause of HCC. The underlying liver disease in the remaining HCC cases, constituting about 5% of the total, is usually not determined, with histological examination revealing only cryptogenic cirrhosis. NASH is thought to be responsible for a substantial portion of such HCC cases, but characteristic pathology is rarely present at the stage of HCC development.. HCC is characterised by extremely frequent intrahepatic recurrence even after successful curative treatments.24 Both surgical hepatectomy and medical ablation are locoregional treatment in that the background liver diseases are left untreated. Liver transplantation forms an exception, after which recurrence is rare if the indication is appropriate. Two modes of intrahepatic recurrence have been distinguished: de novo ...
Clinical trial for HEPATIC NEOPLASM | HEPATOCELLULAR CARCINOMA , A Study of Nivolumab in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
Clinical trial for HEPATIC NEOPLASM | HEPATOCELLULAR CARCINOMA , A Study of Nivolumab in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
BACKGROUND: Sorafenib is the recommended treatment for patients with advanced hepatocellular carcinoma. We aimed to compare the efficacy and safety of sorafenib to that of selective internal radiotherapy (SIRT) with yttrium-90 ((90)Y) resin microspheres in patients with hepatocellular carcinoma. METHODS: SARAH was a multicentre, open-label, randomised, controlled, investigator-initiated, phase 3 trial done at 25 centres specialising in liver diseases in France. Patients were eligible if they were aged at least 18 years with a life expectancy greater than 3 months, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, Child-Pugh liver function class A or B score of 7 or lower, and locally advanced hepatocellular carcinoma (Barcelona Clinic Liver Cancer [BCLC] stage C), or new hepatocellular carcinoma not eligible for surgical resection, liver transplantation, or thermal ablation after a previously cured hepatocellular carcinoma (cured by surgery or thermoablative ...
A new study published in the Journal of the National Cancer Institute concluded that high consumption of vitamin E from diet or supplements may lower the risk of liver cancer. Although we rarely hear about liver cancer, it is the third most common cause of cancer mortality in the world and a large percentage of these occurs in developing countries.. Data was analyzed from 132,737 people in China who were enrolled in the Shanghai Womens Health Study from 1997 to 2000, or the Shanghai Mens Health Study from 2002 to 2006.. In-person interviews to gather data on dietary habits were conducted using validated food-frequency questionaires. Questions were included on how often participants ate some of the most commonly consumed Shanghai foods and whether or not they took vitamin supplements. Liver cancer risk was then determined between those with high and low vitamin E intake.. There were 267 liver cancer patients (118 women and 149 men) diagnosed between 2 years after study enrollment and an average ...
Fibrolamellar hepatocellular carcinoma (FL-HCC) is generally a fairly rare event in routine pathology practice. This variant of hepatocellular carcinoma (HCC) is peculiarly intriguing and,in addition, poorly understood. Young people or children are often the target individuals with this type of cancer. Previously, I highlighted some pathology aspects of FL-HCC, but in this review, the distinctive clinico-pathologic features of FL-HCC and the diagnostic pathologic criteria of FL-HCC are fractionally reviewed and expanded upon. Further, molecular genetics update data with reference to this specific tumor are particularly highlighted as a primer for general pathologists and pediatric histopathologists. FL-HCC may present with metastases, and regional lymph nodes may be sites of metastatic spread. However, peritoneal and pulmonary metastatic foci have also been reported. To the best of our knowledge, FL-HCC was initially considered having an indolent course, but survival outcomes have recently been updated
Liver Cancer (hepatocellular carcinoma). Medical Term: None Specified. Description:. A malignant tumor arising from liver cells. Although much less common than metastatic liver cancer in most areas of the world, hepatocellular carcinoma is the most common internal malignancy and an important cause of death in certain areas of Africa and Southeast Asia. This is mainly because of the high incidence of Hepatitis B in these areas.. In North America, hepatocellular carcinoma is mainly associated with cirrhosis of the liver.. Causes: Unknown. As noted above, there is a high association with Hepatitis B and C, and cirrhosis of liver.. Prevention: Hepatitis B vaccination and prevention education for high-risk individuals. Minimize alcohol use.. Signs & Symptoms. ...
TY - JOUR. T1 - Surgical Resection vs. Ablative Therapies Through a Laparoscopic Approach for Hepatocellular Carcinoma: a Comparative Study. AU - Santambrogio, Roberto. AU - Santambrogio, Roberto. AU - Barabino, Matteo. AU - Bruno, Savino. AU - Mariani, Nicolò. AU - Maroni, Nirvana. AU - Bertolini, Emanuela. AU - Franceschelli, Giuseppe. AU - Opocher, Enrico. PY - 2017/12/12. Y1 - 2017/12/12. N2 - © 2017 The Society for Surgery of the Alimentary Tract Background: When compatible with the liver functional reserve, laparoscopic hepatic resection remains the treatment of choice for hepatocellular carcinoma while laparoscopic ablation therapies appear as a promising less invasive alternative. The aim of the study is to compare two homogeneous groups of patients submitted to either hepatic resection or thermoablation for the treatment of single hepatocellular carcinoma (≤ 3 cm). Methods: We enrolled 264 cirrhotic patients out of 905 cases consecutively evaluated for hepatocellular carcinoma. We ...
Objective: To investigate the prognostic relationship between the expression levels of periostin (POSTN) in hepatocellular carcinoma (HCC) tissues as well as its effect in invasion and metastasis. Methods: The expression levels of POSTN in liver cancer tissues were detected with real-time quantitative PCR (QPCR) and immunohistochemistry (IHC). Kaplan-Meier method and Log-rank test were used to analyze the relationship between POSTN expression level and postoperative prognosis in patients with liver cancer. The expression of POSTN in hepatocellular carcinoma cells with different metastasis characteristics were detected in vitro and the overexpression of POSTN in low metastatic hepatocellular carcinoma cells was mediated through plasmid transfection techniques. The effects of POSTN on invasion and metastasis of hepatocellular carcinoma cells were determined by transwell migration and matrigel invasion assay. The comparative expression level of POSTN was analyzed by t-test. Results: The expression ...
Abdominal ultrasonograms are often obtained for the initial evaluation of patients with abdominal pain; therefore, ultrasonography may be the first imaging study available in patients with fibrolamell... more